Lumen Bioscience Awarded Up to $7M to Advance Phase 1 Clinical Development of Host-Directed Antiviral Countermeasure

Seattle-based Lumen Bioscience has been awarded up to $7M from the Department of War to support Phase 1 clinical development of LMN-1001, a host directed, investigational intranasal antiviral candidate. The funding will support a Phase 1 trial evaluating the safety, tolerability, and pharmacologic activity of LMN-1001 in healthy volunteers.